Roivant (ROIV) Director Meghan Fitzgerald Sells Shares

What Happened

• Meghan Fitzgerald, a director of Roivant Sciences Ltd. (ROIV), sold a total of 5,112 common shares in open-market transactions on September 15, 2026 for aggregate proceeds of $203,152.
  • 4,712 shares sold at a weighted-average price of $39.68 for $186,972 (multiple trades).
  • 400 shares sold at a weighted-average price of $40.45 for $16,180 (multiple trades).
• These were sales (not purchases), so they are generally routine liquidity events rather than a direct bullish signal.

Key Details

• Transaction dates and prices:
  • 2026-09-15 — 4,712 shares; weighted avg price $39.68; price range reported $39.26–$40.25 (Footnote F1).
  • 2026-09-15 — 400 shares; weighted avg price $40.45; price range reported $40.28–$40.51 (Footnote F2).
• Total shares sold: 5,112; total proceeds: $203,152.
• Both sets of sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026 (preplanned trades).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Report filed Sept 17, 2026 — within the SEC’s typical two-business-day Form 4 reporting window.

Context

• A Rule 10b5-1 plan means the trades were pre-arranged and typically indicate the sales were planned in advance, reducing their informational significance about the insider’s current view of the company.
• For retail investors, purchases are generally more informative than routine sales; these transactions appear to be planned dispositions rather than opportunistic insider buys.